1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hereditary Cancer Testing Market Size Growth Rate by Type: 2018 VS 2022 VS 2032
1.2.2 RNA Testing
1.2.3 DNA Testing
1.3 Market by Application
1.3.1 Global Hereditary Cancer Testing Market Share by Application: 2018 VS 2022 VS 2032
1.3.2 Breast Cancer
1.3.3 Gastrointestinal Cancer
1.3.4 Prostate Cancer
1.3.5 Respiratory/Lung Cancer
1.3.6 Other Cancers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Hereditary Cancer Testing Market Perspective (2018-2032)
2.2 Hereditary Cancer Testing Growth Trends by Region
2.2.1 Hereditary Cancer Testing Market Size by Region: 2018 VS 2022 VS 2032
2.2.2 Hereditary Cancer Testing Historic Market Size by Region (2018-2023)
2.2.3 Hereditary Cancer Testing Forecasted Market Size by Region (2023-2032)
2.3 Hereditary Cancer Testing Market Dynamics
2.3.1 Hereditary Cancer Testing Industry Trends
2.3.2 Hereditary Cancer Testing Market Drivers
2.3.3 Hereditary Cancer Testing Market Challenges
2.3.4 Hereditary Cancer Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hereditary Cancer Testing Players by Revenue
3.1.1 Global Top Hereditary Cancer Testing Players by Revenue (2018-2023)
3.1.2 Global Hereditary Cancer Testing Revenue Market Share by Players (2018-2023)
3.2 Global Hereditary Cancer Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hereditary Cancer Testing Revenue
3.4 Global Hereditary Cancer Testing Market Concentration Ratio
3.4.1 Global Hereditary Cancer Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hereditary Cancer Testing Revenue in 2022
3.5 Hereditary Cancer Testing Key Players Head office and Area Served
3.6 Key Players Hereditary Cancer Testing Product Solution and Service
3.7 Date of Enter into Hereditary Cancer Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hereditary Cancer Testing Breakdown Data by Type
4.1 Global Hereditary Cancer Testing Historic Market Size by Type (2018-2023)
4.2 Global Hereditary Cancer Testing Forecasted Market Size by Type (2023-2032)
5 Hereditary Cancer Testing Breakdown Data by Application
5.1 Global Hereditary Cancer Testing Historic Market Size by Application (2018-2023)
5.2 Global Hereditary Cancer Testing Forecasted Market Size by Application (2023-2032)
6 North America
6.1 North America Hereditary Cancer Testing Market Size (2018-2032)
6.2 North America Hereditary Cancer Testing Market Size by Country (2018-2023)
6.3 North America Hereditary Cancer Testing Market Size by Country (2023-2032)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Hereditary Cancer Testing Market Size (2018-2032)
7.2 Europe Hereditary Cancer Testing Market Size by Country (2018-2023)
7.3 Europe Hereditary Cancer Testing Market Size by Country (2023-2032)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hereditary Cancer Testing Market Size (2018-2032)
8.2 Asia-Pacific Hereditary Cancer Testing Market Size by Country (2018-2023)
8.3 Asia-Pacific Hereditary Cancer Testing Market Size by Country (2023-2032)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Hereditary Cancer Testing Market Size (2018-2032)
9.2 Latin America Hereditary Cancer Testing Market Size by Country (2018-2023)
9.3 Latin America Hereditary Cancer Testing Market Size by Country (2023-2032)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hereditary Cancer Testing Market Size (2018-2032)
10.2 Middle East & Africa Hereditary Cancer Testing Market Size by Country (2018-2023)
10.3 Middle East & Africa Hereditary Cancer Testing Market Size by Country (2023-2032)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Ambry Genetics (Konica Minota)
11.1.1 Ambry Genetics (Konica Minota) Company Detail
11.1.2 Ambry Genetics (Konica Minota) Business Overview
11.1.3 Ambry Genetics (Konica Minota) Hereditary Cancer Testing Introduction
11.1.4 Ambry Genetics (Konica Minota) Revenue in Hereditary Cancer Testing Business (2018-2023)
11.1.5 Ambry Genetics (Konica Minota) Recent Development
11.2 Asper Biogene
11.2.1 Asper Biogene Company Detail
11.2.2 Asper Biogene Business Overview
11.2.3 Asper Biogene Hereditary Cancer Testing Introduction
11.2.4 Asper Biogene Revenue in Hereditary Cancer Testing Business (2018-2023)
11.2.5 Asper Biogene Recent Development
11.3 Natera
11.3.1 Natera Company Detail
11.3.2 Natera Business Overview
11.3.3 Natera Hereditary Cancer Testing Introduction
11.3.4 Natera Revenue in Hereditary Cancer Testing Business (2018-2023)
11.3.5 Natera Recent Development
11.4 Caris Life Sciences
11.4.1 Caris Life Sciences Company Detail
11.4.2 Caris Life Sciences Business Overview
11.4.3 Caris Life Sciences Hereditary Cancer Testing Introduction
11.4.4 Caris Life Sciences Revenue in Hereditary Cancer Testing Business (2018-2023)
11.4.5 Caris Life Sciences Recent Development
11.5 BioReference Laboratories (GeneDx)
11.5.1 BioReference Laboratories (GeneDx) Company Detail
11.5.2 BioReference Laboratories (GeneDx) Business Overview
11.5.3 BioReference Laboratories (GeneDx) Hereditary Cancer Testing Introduction
11.5.4 BioReference Laboratories (GeneDx) Revenue in Hereditary Cancer Testing Business (2018-2023)
11.5.5 BioReference Laboratories (GeneDx) Recent Development
11.6 LabSolutions
11.6.1 LabSolutions Company Detail
11.6.2 LabSolutions Business Overview
11.6.3 LabSolutions Hereditary Cancer Testing Introduction
11.6.4 LabSolutions Revenue in Hereditary Cancer Testing Business (2018-2023)
11.6.5 LabSolutions Recent Development
11.7 Progenity?Inc
11.7.1 Progenity?Inc Company Detail
11.7.2 Progenity?Inc Business Overview
11.7.3 Progenity?Inc Hereditary Cancer Testing Introduction
11.7.4 Progenity?Inc Revenue in Hereditary Cancer Testing Business (2018-2023)
11.7.5 Progenity?Inc Recent Development
11.8 ARUP Laboratories
11.8.1 ARUP Laboratories Company Detail
11.8.2 ARUP Laboratories Business Overview
11.8.3 ARUP Laboratories Hereditary Cancer Testing Introduction
11.8.4 ARUP Laboratories Revenue in Hereditary Cancer Testing Business (2018-2023)
11.8.5 ARUP Laboratories Recent Development
11.9 Myriad
11.9.1 Myriad Company Detail
11.9.2 Myriad Business Overview
11.9.3 Myriad Hereditary Cancer Testing Introduction
11.9.4 Myriad Revenue in Hereditary Cancer Testing Business (2018-2023)
11.9.5 Myriad Recent Development
11.10 NeoGenomics
11.10.1 NeoGenomics Company Detail
11.10.2 NeoGenomics Business Overview
11.10.3 NeoGenomics Hereditary Cancer Testing Introduction
11.10.4 NeoGenomics Revenue in Hereditary Cancer Testing Business (2018-2023)
11.10.5 NeoGenomics Recent Development
11.11 Blueprint Genetics
11.11.1 Blueprint Genetics Company Detail
11.11.2 Blueprint Genetics Business Overview
11.11.3 Blueprint Genetics Hereditary Cancer Testing Introduction
11.11.4 Blueprint Genetics Revenue in Hereditary Cancer Testing Business (2018-2023)
11.11.5 Blueprint Genetics Recent Development
11.12 CellMax Life
11.12.1 CellMax Life Company Detail
11.12.2 CellMax Life Business Overview
11.12.3 CellMax Life Hereditary Cancer Testing Introduction
11.12.4 CellMax Life Revenue in Hereditary Cancer Testing Business (2018-2023)
11.12.5 CellMax Life Recent Development
11.13 Fulgent Genetics
11.13.1 Fulgent Genetics Company Detail
11.13.2 Fulgent Genetics Business Overview
11.13.3 Fulgent Genetics Hereditary Cancer Testing Introduction
11.13.4 Fulgent Genetics Revenue in Hereditary Cancer Testing Business (2018-2023)
11.13.5 Fulgent Genetics Recent Development
11.14 Strand Life Sciences
11.14.1 Strand Life Sciences Company Detail
11.14.2 Strand Life Sciences Business Overview
11.14.3 Strand Life Sciences Hereditary Cancer Testing Introduction
11.14.4 Strand Life Sciences Revenue in Hereditary Cancer Testing Business (2018-2023)
11.14.5 Strand Life Sciences Recent Development
11.15 Myogenes
11.15.1 Myogenes Company Detail
11.15.2 Myogenes Business Overview
11.15.3 Myogenes Hereditary Cancer Testing Introduction
11.15.4 Myogenes Revenue in Hereditary Cancer Testing Business (2018-2023)
11.15.5 Myogenes Recent Development
11.16 LabCorp
11.16.1 LabCorp Company Detail
11.16.2 LabCorp Business Overview
11.16.3 LabCorp Hereditary Cancer Testing Introduction
11.16.4 LabCorp Revenue in Hereditary Cancer Testing Business (2018-2023)
11.16.5 LabCorp Recent Development
11.17 Quest Diagnostics
11.17.1 Quest Diagnostics Company Detail
11.17.2 Quest Diagnostics Business Overview
11.17.3 Quest Diagnostics Hereditary Cancer Testing Introduction
11.17.4 Quest Diagnostics Revenue in Hereditary Cancer Testing Business (2018-2023)
11.17.5 Quest Diagnostics Recent Development
11.18 Pathway Genomics
11.18.1 Pathway Genomics Company Detail
11.18.2 Pathway Genomics Business Overview
11.18.3 Pathway Genomics Hereditary Cancer Testing Introduction
11.18.4 Pathway Genomics Revenue in Hereditary Cancer Testing Business (2018-2023)
11.18.5 Pathway Genomics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
